Palette Life Sciences and Nestlé Skin Health Enter into Global Licensing Agreement for Deflux, Solesta and Barrigel

Transaction creates a fully-integrated specialty pharmaceutical company focused on improving patient outcomes for urology & urogynecology disorders, colorectal conditions, radiotherapy and interventional oncology procedures  

STOCKHOLM, Oct. 15, 2018 /PRNewswire/ -- Palette Life Sciences AB (formerly known as Pharmanest AB*) has entered into definitive agreements with Nestlé Skin Health to license worldwide commercialization and development rights for Deflux, Solesta and Barrigel. Palette is currently developing Lidbree for pain relief for gynecological applications.

Key highlights for the Nestlé Skin Health transaction include:

• Exclusive rights to fully develop and commercialize the three products:
• • Deflux – the only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage.
  • Solesta – the only FDA-approved injectable treatment for fecal incontinence, which is also cleared for commercialization in Europe. Fecal incontinence is a debilitating health problem afflicting about 2% of people worldwide with four times more prevalence in women than men.
  • Barrigel – a biodegradable injectable treatment for protection of the rectal wall when treating prostate cancer with radiation. The product is approved in Europe and will be further developed for future market introduction in the US.
• Palette Life Sciences will focus immediately on commercialization activities for Deflux and Solesta, and will begin activities to enable worldwide commercialization of Barrigel.
• The license can enable future new products intended for management of urological and gastroenterological conditions, and protection of adjacent healthy organs and tissue during radiation therapy for cancer.
• The products are all based on the Nestlé Skin Health's well-known and widely utilized NASHA technology. Millions of patients have been treated with NASHA based products for various medical conditions world-wide. The most well-known NASHA product marketed by Nestlé Skin Health is Restylane, a leading dermal filler.
• Nestlé Skin Health will continue to manufacture the licensed products on behalf of Palette Life Sciences.
• As part of the transaction, Pharmanest AB will be renamed Palette Life Sciences AB with offices in Sweden and the US.

*Name change pending